Results 61 to 70 of about 49,464 (141)

Use of capecitabine in management of early colon cancer

Cancer Management and Research, 2011
H Hameed, J CassidyBeatson West of Scotland Cancer Centre, Glasgow, Scotland, UKAbstract: Capecitabine (Xeloda®, Roche, Basel, Switzerland) is a pro-drug of 5-fluorouracil (5-FU), and it is converted to 5-FU in the cancer cell by enzymatic ...
Cassidy J, Hameed H
doaj  

Surgery-first versus neoadjuvant chemotherapy in stage I (cT1c) triple-negative breast cancer: A critical reappraisal. [PDF]

Breast
Dediu M, Zielinski C, Preoteasa V, Bulzan A.   +3 more
europepmc   +1 more source

Adverse events of capecitabine in gastric cancer patients: a real-world pharmacovigilance study based on the FAERS database. [PDF]

Front Pharmacol
Sang R, Zhu M, Mao J, Wu Y, Qin S, Wang L.   +5 more
europepmc   +1 more source

Health Literacy and Capecitabine Adherence in a Remote Monitoring Pilot Trial for Breast Cancer: Post Hoc Exploratory Analysis. [PDF]

JMIR Form Res
Hernandez S, Meisel J, Sadigh G, Graetz I.   +3 more
europepmc   +1 more source

Real-world clinical outcomes of patients with early-stage TNBC and BRCAm who were treated with adjuvant capecitabine in the United States. [PDF]

Breast Cancer Res Treat
Lynce F, Ru M, Luo L, Miranda M, Xu X, Isaacs C.   +5 more
europepmc   +1 more source

The Effect of Two Different Pharmacist-led Educations Provided to Patients with Colorectal Cancer Receiving an Oral Antineoplastic Agent: A Comparative Interventional Study. [PDF]

J Res Pharm Pract
Amiri R, Mansouri A, Taghizadeh-Ghehi M, Rafsanjani ZJ, Kohneloo AJ, Emami SA.   +5 more
europepmc   +1 more source

Efficacy and safety of traditional Chinese medicine herbal hand-foot bath combined with arnebia oil for chemotherapy-induced hand-foot syndrome refractory to standard treatment: a single-arm prospective interventional pilot study of 30 cases. [PDF]

Front Med (Lausanne)
Chen Y, Jin Y, Fu L, Song P, Shao Z, Tan Y.   +5 more
europepmc   +1 more source

Clinical management of adverse events in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine. [PDF]

Oncologist
Okines AFC, Roesch E, Watkins K, Pitner MK, Hutchinson KM, Simon S, Yan F.   +6 more
europepmc   +1 more source

Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis. [PDF]

Front Oncol
Li Y, Li Z, Shi X, Zuo H.
europepmc   +1 more source

Trastuzumab-Conjugated Nanoliposomes for Targeted Capecitabine Delivery to Suppress HER2-Positive Breast Tumor: Efficacy Analysis in NOD SCID Mice Xenografts. [PDF]

Int J Nanomedicine
Das S, Satapathy BS, Rahamathulla M, Alhamhoom Y, Pattanaik S, Chawla S, Pattnaik G, Rath D, Ahmed MM, Pasha I.   +9 more
europepmc   +1 more source